

The Medical Letter[®]

on Drugs and Therapeutics

Volume 68

March 30, 2026

ISSUE No.
1751

IN THIS ISSUE

In Brief: Aflibercept (*Eylea HD*) for Macular Edema Following Retinal Vein Occlusionp 56

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769**

The Medical Letter®

on Drugs and Therapeutics

Volume 68 (Issue 1751)

March 30, 2026

Take CME Exams

IN BRIEF

Aflibercept (*Eylea HD*) for Macular Edema Following Retinal Vein Occlusion

Eylea HD (Regeneron), which contains 8 mg of the vascular endothelial growth factor (VEGF) inhibitor aflibercept, has now been approved by the FDA for intravitreal treatment of macular edema following retinal vein occlusion (RVO). A 2-mg dose of aflibercept (*Eylea*) was approved previously for this indication. *Eylea* and *Eylea HD* are also approved for treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.¹

A CLINICAL STUDY – Approval of *Eylea HD* for the new indication was based on the results of a double-masked trial (QUASAR) in 892 adults with macular edema following RVO. Patients were randomized to receive aflibercept 8 mg once monthly for 3 or 5 months and then every 8 weeks or aflibercept 2 mg every 4 weeks. Improvements from baseline in best-corrected visual acuity at week 36 with aflibercept 8 mg were noninferior to those with the 2-mg dose.²

ADVERSE EFFECTS – Common adverse effects (>3%) of *Eylea HD* in the QUASAR trial were increased intraocular pressure, blurred vision, conjunctival hemorrhage, vitreous detachment, ocular discomfort, pain, and irritation. In clinical trials for other indications, cataracts and vitreous floaters were common. Retinal vasculitis and scleritis and endophthalmitis have been reported with aflibercept.

Arterial thrombotic events (nonfatal stroke, myocardial infarction, vascular death) have been reported following intravitreal use of VEGF inhibitors, including aflibercept.

DOSAGE, ADMINISTRATION, AND COST – The recommended dosage of *Eylea HD* for treatment of macular edema following RVO is 8 mg administered by intravitreal injection once every 4 weeks for the first 3 to 5 doses, followed by 8 mg every 8 weeks thereafter. An every-4-week interval can be used if a response is not maintained with every-8-week dosing. One 8-mg vial of *Eylea HD* costs \$2813; one 2-mg vial of *Eylea* costs \$2001.³

OTHER INDICATIONS – The FDA also approved an every-4-week maintenance dosing option of *Eylea HD* for the other three indications. According to the manufacturer, some patients do not maintain an adequate response when switched from monthly to extended dosing intervals (every 8 or 12 weeks) and may benefit from resuming monthly injections. ■

1. Aflibercept (*Eylea*) for age-related macular degeneration. *Med Lett Drugs Ther* 2012; 54:9.
2. NIH. A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced vision due to swelling in the macula, central part of the retina caused by a blocked vein in the retina (macula edema secondary to retinal vein occlusion) (QUASAR). NCT05850520. Available at: <https://bit.ly/4aVg2Gn>. Accessed March 12, 2026.
3. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. March 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/policies/drug-pricing-policy.

We Want to Know

Are there topics you would like us to review in an upcoming issue? We welcome your suggestions at: articles@medicalletter.org

PRESIDENT, EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **EDITOR IN CHIEF EMERITUS:** Mark Abramowicz, M.D.; **VICE PRESIDENT, ADMINISTRATION:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., B.C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Dartmouth Hitchcock Medical Center; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
The Medical Letter, Inc.
2 Madison Ave, Ste 211
Larchmont, NY 10538
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
1 year – \$179; \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints – \$45 per issue or article

Site License Inquiries:
E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:     

Copyright 2026. ISSN 1523-2859

The
Medical
Letter